Acadia Healthcare Company, Inc. (NASDAQ:ACHC) President Brent Turner sold 206,252 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $50.69, for a total value of $10,454,913.88. Following the completion of the sale, the president now owns 81,106 shares of the company’s stock, valued at $4,111,263.14. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Acadia Healthcare Company, Inc. (NASDAQ ACHC) opened at 45.55 on Friday. The stock’s 50 day moving average price is $50.20 and its 200-day moving average price is $45.31. Acadia Healthcare Company, Inc. has a one year low of $32.54 and a one year high of $54.34. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of 500.55 and a beta of 1.15.
Acadia Healthcare (NASDAQ:ACHC) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.01. Acadia Healthcare had a return on equity of 8.69% and a net margin of 0.30%. The business had revenue of $715.90 million during the quarter, compared to analyst estimates of $717.38 million. During the same period in the prior year, the company earned $0.73 earnings per share. Acadia Healthcare’s revenue was down 5.4% compared to the same quarter last year. On average, equities research analysts expect that Acadia Healthcare Company, Inc. will post $2.45 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://stocknewstimes.com/2017/08/25/acadia-healthcare-company-inc-achc-president-sells-10454913-88-in-stock.html.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of Acadia Healthcare by 65.6% in the second quarter. BlackRock Inc. now owns 8,523,077 shares of the company’s stock valued at $420,871,000 after buying an additional 3,377,291 shares during the period. JPMorgan Chase & Co. raised its position in shares of Acadia Healthcare by 0.8% in the first quarter. JPMorgan Chase & Co. now owns 7,705,975 shares of the company’s stock valued at $335,980,000 after buying an additional 59,735 shares during the period. Vanguard Group Inc. raised its position in shares of Acadia Healthcare by 8.9% in the second quarter. Vanguard Group Inc. now owns 6,254,532 shares of the company’s stock valued at $308,849,000 after buying an additional 511,299 shares during the period. Aristotle Capital Management LLC purchased a new position in shares of Acadia Healthcare during the first quarter valued at $140,071,000. Finally, FMR LLC raised its position in shares of Acadia Healthcare by 26.4% in the second quarter. FMR LLC now owns 2,775,451 shares of the company’s stock valued at $137,052,000 after buying an additional 580,449 shares during the period.
Several equities research analysts recently weighed in on the company. BidaskClub lowered Acadia Healthcare from a “hold” rating to a “sell” rating in a report on Friday, August 18th. Zacks Investment Research lowered Acadia Healthcare from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Deutsche Bank AG boosted their target price on Acadia Healthcare from $58.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, July 31st. Craig Hallum restated a “buy” rating and issued a $65.00 target price (up from $52.00) on shares of Acadia Healthcare in a report on Monday, July 31st. Finally, UBS AG restated a “positive” rating and issued a $60.00 target price (up from $54.00) on shares of Acadia Healthcare in a report on Monday, July 31st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $59.21.
About Acadia Healthcare
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Receive News & Ratings for Acadia Healthcare Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
